NeuBase Therapeutics, Inc. (NBSE)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.1890 |
| Open | 0.1890 |
| Bid | 0.1779 x 3000 |
| Ask | 0.1889 x 40000 |
| Day's Range | 0.1630 - 0.1898 |
| 52 Week Range | 0.1630 - 2.0800 |
| Volume | |
| Avg. Volume | 357,448 |
| Market Cap | 5.703M |
| Beta (5Y Monthly) | 0.89 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for NBSE
Related Research
- NeuBase Therapeutics, Inc.Analyst Report: Regeneron Pharmaceuticals, Inc.Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).RatingFair ValueEconomic Moat3 days agoMorningstar
- GlobeNewswire
NeuBase Therapeutics Reports Business Update and Financial Results for the First Quarter of Fiscal Year 2023
PITTSBURGH, Feb. 14, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today reported its financial results for the three-month period ended December 31, 2022, and other recent developments. “We plan on leveraging our PATrOL™ platform to perform ‘nuclease free’ in vivo gene editing to restore healthy gene funct
- GlobeNewswire
NeuBase Therapeutics Reports Business Update and Financial Results for Fiscal Year 2022
PITTSBURGH, Dec. 21, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today reported its financial results for the fiscal year ended September 30, 2022, and other recent developments. “Fiscal year 2022 was a challenging period in our Company’s history as we faced a tightening of the broader capital markets for
- GlobeNewswire
NeuBase Therapeutics Announces Gene Editing Research Agreement with Global Healthcare Company
PITTSBURGH, Oct. 21, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, today announced a research agreement with a Top 10 Global Healthcare company (“Healthcare Company”) (based on 2021 revenues). For this research, the Healthcare Company will evaluate NeuBase’s PATrOL™ technology for three monogenic genetic di
